Insulin glulisine in the management of diabetes
Satoru Yamada1,21Diabetes Center, Kitasato Institute Hospital, Tokyo, Japan; 2Department of Internal Medicine, Keio University School of Medicine, Tokyo, JapanAbstract: Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/81881391964b4acc90bccbf4114255c3 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Satoru Yamada1,21Diabetes Center, Kitasato Institute Hospital, Tokyo, Japan; 2Department of Internal Medicine, Keio University School of Medicine, Tokyo, JapanAbstract: Insulin glulisine is appealing in principle, but the advantages of this drug over the other rapid-acting insulin analogs are still relatively unknown. The frequency of hypoglycemia, convenience in the timing of administration, and improvements in terms of HbA1c seem similar among the rapid-acting insulin analogs, including insulin glulisine. Only properly randomized long-term clinical studies with insulin glulisine will reveal the true value of this novel insulin analog.Keywords: insulin analog, rapid-acting insulin, trometamol, polysorbate 20 |
|---|